Latest Conference Articles

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Leonard G. Gomella, MD, told attendees at the 8th Annual IPCC that the decision to screen or not to screen for prostate cancer boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

Physicians should engage in careful patient selection before recommending active surveillance for prostate cancer, according to Mitchell C. Benson, MD.

In a similar fashion as astronauts, physicians can mitigate risks and improve outcomes with advanced planning and teamwork, four-time space shuttle commander Tom Henricks said during his keynote address at the Interdisciplinary Prostate Cancer Congress.

Richard Stock, MD, a professor of radiation oncology at the Icahn School of Medicine at Mount Sinai Hospital, talks about brachytherapy and its benefits for patients with prostate cancer.

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.

Deanna J. Attai, MD, FACS, who interacts with her thousands of followers on Twitter, Facebook, YouTube, her blog, and other social media platforms, recently educated other physicians on what their role can be on social media.

Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype and a retrospective analysis about the impact of radiation after breast conserving surgery took home top honors at the Miami Breast Cancer Conference this year.

A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.

Compelling clinical trial evidence supports the use of hypofractionated radiation as the standard of care for postmenopausal women with luminal A tumors and node-negative disease.

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Ramucirumab added to docetaxel significantly improved PFS compared with docetaxel monotherapy as second-line treatment in a phase II study of patients with metastatic transitional cell carcinoma.

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

In patients evaluable for treatment response, the ORR with the combination was 50%, with 11% having a CR.

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.